

PRESS RELEASE

9 November 2022

Capricorn Partners joins in a € 10 million Pre-Series A financing round in neotiv to accelerate Alzheimer's diagnosis

Magdeburg-based digital health company neotiv, which is working on the development of digital biomarkers for early Alzheimer's screening, has successfully expanded its Pre-Series A financing round and raised 10 million euros. With the additional funds, neotiv is now able to drive nationwide supply of the neotivCare® app, accelerate internationalization, and fight Alzheimer's.

The funding of 10 million euros is led by renowned investors Capricorn Partners via their Capricorn Digital Growth Fund, High-Tech Gründerfonds and bmp with IBG Fonds. Convergence Partners, RSJ Investments as well as Sana Future GmbH and Vega Ventures are also participating. Strong partners are thus driving the expansion of the company, which was founded in 2017 and whose focus is the neotivCare® app. Using digital memory tests, the neotivCare® app supports people with subjective cognitive decline (SCD), their relatives and doctors in diagnosing mild cognitive impairment (MCI).

Dr Chris Rehse, CEO and co-founder of neotiv, notes:

“ This financing round illustrates the support of renowned international investors for our successful science transfer. Above all, this will benefit patients. neotiv has set itself the goal of making an important contribution to the fight against Alzheimer's disease. The funds provided will enable neotiv to further develop targeted platform solutions in the area of patient journeys in the coming years and thus also advance the company economically.”

Detecting memory problems early - combat Alzheimer's disease

neotivCare® is a CE labelled medical device classified as risk class I that also meets the strict data protection requirements for digital health applications. The basis for neotiv's digital memory tests are research results from scientific collaborations in Germany and international studies.

Worldwide, the number of dementia patients with Alzheimer's disease is estimated at 32 million. Another 69 million are in the prodromal phase of the disease, which indicates mild cognitive impairment (MCI) due to initial episodic memory impairment.¹

Dr David Berron, Chief Science Officer and co-founder of neotiv, states:

“ Mild cognitive impairment (MCI) is an important clinical gateway for early prevention and intervention of Alzheimer's disease. However, diagnosing the memory deficits typical of MCI in routine care is a major challenge because available screening methods cannot detect them. This is exactly where neotiv kicks in.”

¹ Gustavsson, A., Norton, N., Fast, T., Frölich, L., Georges, J., Holzapfel, D., Kirabali, T., Krolak-Salmon, P., Rossini, P. M., Ferretti, M. T., Lanman, L., Chadha, A. S., & van der Flier, W. M. (2022). Global estimates on the number of persons across the Alzheimer's disease continuum. *Alzheimer's & Dementia*, 1–13. <https://doi.org/10.1002/alz.12694>



PRESS RELEASE

9 November 2022

Contribution to primary care of the future

Working closely with physicians, healthcare insurers and strategic pharmaceutical partners, neotiv has revolutionized the patient journey for people with subjective cognitive decline and implemented it in regional as well as nationwide care programs. The digital cognitive tests have now been used in 5,250 cases in care programs, citizen research and clinical trials.

Antoine D'Hollander, Investment Manager at Capricorn Partners, says:

“ neotiv fits perfectly within the strategy of the Capricorn Digital Growth Fund to invest in data driven companies improving healthcare at lower cost. We invested in the company since we believe MCI is a major societal challenge requiring a solid diagnostic tool. neotiv has proven to offer a scientifically validated and easy solution applicable to this market. Together with the other investors, we strive to further scale neotiv's business within and outside Germany.”

Increased chances of approval for drugs with a disease-modifying approach

Although there is currently no cure for Alzheimer's disease, researchers around the world are working hard to develop new therapies, especially drugs with a disease-modifying approach². These drugs target the protein deposits in the brain that are characteristic of Alzheimer's disease and are associated with the destruction of nerve cells. The recently published positive results from the Phase 3 trial of Lecanemab³ are likely to be followed by others, further increasing the chance of drug approval in the US and Europe.

Prof Dr med. Emrah Düzel, Chief Medical Officer and co-founder of neotiv:

“ The technological basis that we have established with neotivCare® allows all physicians to examine suspicious cases of MCI in a reliable and low- threshold manner in view of increasing case numbers. As a result, we are already improving the care of patients with memory problems and are uniquely positioned to deliver medications with a disease-modifying approach to patients quickly and inclusively.”

Follow the link to download image material: <https://neotiv.com/en/press>

² Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development pipeline: 2021. *Alzheimers Dement* (N Y). 2021 May 25;7(1):e12179. doi: 10.1002/trc2.12179. PMID: 34095440; PMCID: PMC8145448.

³ <https://eisai.mediaroom.com/2022-09-27-LECANEMAB-CONFIRMATORY-PHASE-3-CLARITY-AD-STUDY-MET-PRIMARY-ENDPOINT,-SHOWING-HIGHLY-STATISTICALLY-SIGNIFICANT-REDUCTION-OF-CLINICAL-DECLINE-IN-LARGE-GLOBAL-CLINICAL-STUDY-OF-1,795-PARTICIPANTS-WITH-EARLY-ALZHEIMERS-DISEASE>

PRESS RELEASE

9 November 2022

About neotiv

neotiv GmbH was founded in 2017 and is headquartered in Magdeburg with an additional office in Berlin. The digital health company is a spin-off of the OVGU Magdeburg in close cooperation with the German Center for Neurodegenerative Diseases (DZNE). The company's goal is to translate the latest findings in neuroscience into products that can be used in science and in the healthcare system. The focus here is on mobile apps for smartphones and tablets. The medical product neotivCare® supports patients in the medical assessment of subjective cognitive decline in order to identify a possible disease, such as Alzheimer's, at an early stage.

www.neotiv.com

About Capricorn Partners

Capricorn Partners is an independent European manager of venture capital and equity funds, investing in innovative European companies with technology as competitive advantage. The investment team of Capricorn is composed of experienced investment managers with deep technology expertise and a broad industrial experience. Capricorn Partners is managing the venture capital funds Capricorn Sustainable Chemistry Fund, Capricorn Digital Growth Fund, Capricorn ICT Arkiv, Capricorn Health-tech Fund, Capricorn Cleantech Fund and Capricorn Fusion China Fund. In addition it is the management company of Quest for Growth, quoted on Euronext Brussels, and the investment manager of Quest Cleantech Fund and Quest+, sub-funds of Quest Management SICAV, registered in Luxembourg.

www.capricorn.be

About High-Tech Gründerfonds

The Seedinvestor High-Tech Gründerfonds (HTGF) finances technology start-ups with growth potential and has supported more than 680 start-ups since 2005. With the launch of its fourth fund, HTGF has over 1.3 billion euros under management. The team of experienced investment managers and start-up experts supports the young companies with know-how, entrepreneurial spirit and passion. The focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemicals and related business areas. More than €4 billion in capital has been invested in the HTGF portfolio by external investors in more than 1,900 follow-on financing rounds to date. In addition, the fund has already successfully sold shares in more than 160 companies. Fund investors in the public-private partnership include the German Federal Ministry for Economic Affairs and Climate Protection, KfW Capital, the Fraunhofer-Gesellschaft and more than 40 companies from a wide range of industries.

<https://www.htgf.de/de/>

About bmp Ventures/IBG Fonds

bmp Ventures is a Berlin-based technology investor with 25 years of active investment experience and therefore one of the most experienced VCs in Germany. Our track record includes 10 managed VC funds, over 260 investments, 120 exits and more than 20 IPOs. Currently, bmp manages the IBG funds, the venture capital funds of the federal state of Saxony-Anhalt. The IBG funds provide venture capital to innovative companies with sustainable and outstanding growth potential in Saxony-Anhalt.

PRESS RELEASE

9 November 2022

About Sana Kliniken AG

Sana Kliniken AG is the leading integrated healthcare provider in the German-speaking region with over 120 facilities (including more than 50 hospitals and ambulatory care facilities), two million patients treated and revenues of three billion euros in 2021. Its shareholders are 25 private health insurance companies. Sana Kliniken AG provides integrated healthcare services for patients and companies, ranging from preventive care, outpatient and inpatient care, follow-up care, rehabilitation and medical aids to B2B services in purchasing, logistics and the medtech sector.

About Convergence

Convergence Partners is a Swiss HealthTech venture capital firm that actively supports the internationalization of its portfolio companies to the 4 largest healthcare markets: US, China, India and Germany. Convergence, which is represented in Switzerland, Germany, Spain and Hong Kong, was established in 2018 by experienced healthcare industry operators and venture capital professionals with them aim to effectively link EU technology excellence with large international scale-up and exit potential. Convergence is focusing on later stage investments in Digital Health, Medical Devices and Diagnostics. Current key investment themes include mental health, women's health and computational biology.

www.convergence-partners.ch

About RSJ Investments

RSJ Investments manages through several sub-funds and open-ended unit funds a broad portfolio of investments into real estate, agriculture, industry, and services. A large percentage of the assets it manages are investments into real estate projects focused on the acquisition of income property, the construction of residential and income real estate and industrial properties. It also focuses on key sectors of the 21st century – information technology, biotechnology, the production of healthy foods and investments aimed at extending and improving human life.

<https://www.rsj.com/en/investments/about-us.html>

About Vega Venture

Vega Ventures is an international venture capital company (private fund). The company focuses on healthcare and its investments follow the forward-looking strategy of supporting patient-centric innovations. Therefore, the partnership with visionary entrepreneurs is the ultimate goal, which is actively and consistently pursued by Vega Ventures' experienced management team when selecting investments.